Scalper1 News
Big pharmas Pfizer (PFE) and Merck (MRK) both beat Q2 estimates and raised guidance Tuesday, while Merck and French counterpart Sanofi (SNY) entered into separate deals to develop immunotherapy drugs for cancer. Pfizer’s earnings dipped 3% to 56 cents a share, but topped analysts’ consensus by 4 cents, according to Thomson Reuters. Sales declined 7% to $11.85 billion, more than $400 million ahead of the Street’s number. Pfizer now sees full-year Scalper1 News
Scalper1 News